Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs
Executive Summary
The US biotech is paying $200m up front in cash and equity investment for the ability to use Merus’ bispecific technology platform in up to 11 programs, which could move beyond cancer and include novel targets and biology. Potential earn-outs under the deal could reach nearly $3bn.
You may also be interested in...
Gilead’s Trispecific Alliance With Merus Continues Its Push In Novel Cancer Tech
Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.
Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Biopharma Quarterly Dealmaking Statistics, Q4 2016
Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.